Navigation Links
BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100)
Date:7/28/2011

inute and 1.5% reported at the end of the first 24 weeks of the Phase 1/2 trial.  Stair climb and pulmonary function are secondary and tertiary endpoints, respectively, in the ongoing prospective Phase 3 trial.
  • The data from the extension study to date support 6-minute walk distance as the primary endpoint and patients with baseline walk distance <325 meters as an entry criteria in the ongoing GALNS Phase 3 trial, given the large and durable effect of the drug on these measures in this population.

  • Simon Jones, Consultant in Paediatric Metabolic Medicine, St. Mary's Hospital, Manchester UK commented, "I'm pleased with the outcome of the GALNS program to date.  The longer-term data look good with sustained improvements in endurance and pulmonary function.  Patients feel stronger and function better than I expected.  All in all, we look forward to the results of the Phase 3 study as it is well designed and will, if successful, support introduction of an important product to patients in need."

    Hank Fuchs, M.D., Chief Medical Officer of BioMarin added, "It's remarkable that improvements in endurance are sustained in spite of the severe and progressive nature of Morquio syndrome.  Patients with Morquio syndrome can miss therapy, for example, due to the need for corrective surgery.  In spite of that, resumption of therapy returns patients to their original state of health or better."Table 1 – Summary of Efficacy Results Through Week 24 of MOR-100 Extension Study Statistic

    MOR-002

    Week 24

    MOR-002

    Week 36

    MOR-100

    Week 0

    MOR-100

    Week 12

    MOR-100

    Week 24Dose

    1.0 mg/kg

    2.0 mg/kg

    1.0 mg/kg for previous 36-48 weeks, Begin 2.0 mg/kg

    2.0 mg/kg

    2.0 mg/kgENDURANCE6 Minute Walk Test – change from Baseline (meters)

    N

    Mean

    (Std. Dev.)

    Median

    16

    17.3

    (74.0)'/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
    2. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
    3. BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET
    4. BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET
    5. BioMarin to Present at the Barclays Capital Global Healthcare Conference
    6. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
    7. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
    8. BioMarin to Present at the Morgan Stanley Healthcare Conference
    9. BioMarin to Present at the Baird Healthcare Conference
    10. BioMarin to Present at the Jefferies Healthcare Conference
    11. BioMarin to Present at the Goldman Sachs Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... Rainbow Scientific, Inc. (RSI), a ... opened an online store to add customer convenience ... developed and manufactured by Biological Industries, Inc. , ... Industries’ Nutristem® serum-free, xeno-free reagents for human mesenchymal ... (hESC) culture. , The online store also ...
    (Date:9/30/2014)... Cambridge MA and Pittsburgh PA (PRWEB) September 30, ... of Clinical Research Nurses ( IACRN), a ... Alliance for Clinical Research Excellence and Safety ... announced the signing of a strategic alliance agreement, ... , IACRN’s vision is to enhance clinical research ...
    (Date:9/29/2014)... , Sept. 29, 2014 Research ... "Oligonucleotide Synthesis Market by Product & Services, End-User , ... their offering. The global oligonucleotide synthesis ... from $1,070.7 million in 2014, growing at a CAGR ... synthesis market is categorized on the basis of products ...
    (Date:9/29/2014)... 2014 According to ... Product (Modifying Enzymes, DNA Polymerase, Acetylase, Methyltransferase, ... Reagents), by Research Area (Developmental Biology, Oncology), ... 2019", published by MarketsandMarkets, provides a detailed ... current market trends, and strategies impacting the ...
    Breaking Biology Technology:Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4
    ... doubled Hectorol sales , Middleton, Wis. Bone ... the work of University of Wisconsin-Madison professor Hector DeLuca, reported ... said its sales of the drug Hectorol were $19.6 million, ... million, despite large theft , Neenah, Wis. ...
    ... Actor Michael J. Fox plans to visit the Waisman ... Jim Doyle and Fox will hold a media event ... for biotechnology research in Wisconsin. , ,In November, Doyle ... biotechnology and stem cell research, including a collective $750 ...
    ... wrote about the importance of transparency, which I described ... and maybe even personal perspectives" so that "intelligent consumers ... and write." , ,This transparency puts content in context, ... where the rules of reportorial journalism, more often than ...
    Cached Biology Technology:Michael J. Fox coming to UW Waisman Center 2Corporations and blogging 2Corporations and blogging 3
    (Date:9/30/2014)... it comes to using marijuana, new research, involving mice ... Journal of Leukocyte Biology , suggests ... that you should. That,s because a team of Italian ... do serious long-term damage to the immune system. This ... diseases, such as multiple sclerosis, inflammatory bowel disease and ...
    (Date:9/30/2014)... with IVF? Here,s some hope: A new research report ... FASEB Journal , explains how scientists developed a ... which induced embryo development in human and mouse eggs ... the sperm cell during fertilization. , "We believe that ... shift in our understanding of human fertilization by providing ...
    (Date:9/30/2014)... perilous threats in today,s ocean. From overfishing and ... coral ecosystems are disappearing at unprecedented rates around ... corals surrounding the island of Moorea in French ... environment: coral guard-crabs. New research from the National ... Seabird McKeon and the museum,s predoctoral fellow Jenna ...
    Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
    ... Scientists have recorded and identified one of the most ... ice as it melts into the sea. The noise, caused ... could provide clues to the rate of glacier melt and ... Geophysicist Erin Pettit, a researcher at the University of Alaska, ...
    ... international team of scientists, including researchers at Columbia University Medical ... malaria parasites require for survival at each stage of infection ... approach to combating malaria, one of the world,s deadliest diseases. ... the journal Nature . "Perhaps the most ...
    ... the Graduate School of Excellence "Materials Science in Mainz" ... Tonhauser. Anna Maria Hofmann received the prize for work ... honored for her thesis on functional polyethylene glycols. The ... prize money of EUR 2,000 and has been given ...
    Cached Biology News:Glaciers sizzle as they disappear into warmer water 2Study finds new vulnerability in malaria parasite 2MAINZ award for Anna Maria Hofmann and Christine Tonhauser 2
    Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
    ... Extraction Kit is manufactured for DNA purification ... byexposure to UV light. The Purification of ... used for DNA-cloning work. The conventional method ... exposure of UV light damages DNA and ...
    CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
    Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
    Biology Products: